Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: Cuomo's cautiously upbeat report at a daily briefing came as the daily death toll across the state, the epicenter of the pandemic in the United States, dropped to 540 on April 17, down from 630 a day earlier and the lowest in more than two weeks. The governor said total hospitalizations of patients being treated for COVID-19, the respiratory illness caused by the coronavirus, came to 16,967, a drop of more than 1,300 over the past three days. Intubations and admissions to intensive care units also continued on their downward trend. "If you look at the past three days, you could argue that we are past the plateau and we're starting to descend which would be very good news," Cuomo said. He said, however, that about 2,000 infected people were newly admitted to hospitals on Friday, which he characterized as "still an overwhelming number," and reiterated that he would take a cautious approach to reopening businesses and schools. Cuomo repeated a call for the federal government to help coordinate and provide funding for the mass testing that he and other governors have said is needed to determine when it is safe for people to go back to work. Providing new details on the challenge, Cuomo said a survey of labs in his state revealed an inability to procure the chemical reagents needed to run the tests on machines supplied by private manufacturers like Roche Holding AG. "They bought the machine, they have the machine, they have the test, but they need the reagents to do a higher volume of tests," Cuomo said, adding that makers like Roche are struggling to get the reagents from China. "That's the logjam we are in." New York disclosed 7,090 new positive cases over the last 24 hours for a total of 236,732 cases, while deaths increased by 540 to 13,362, marking by far the largest number of fatalities of any state. Even with stabilizing numbers, Cuomo said the pandemic was taking a severe emotional and economic toll on people, and estimated the impact on society would prove to be the biggest challenge facing the country since World War Two. "On every level this is a terrible experience, Cuomo said. "It is as tumultuous a time as we have ever seen." Claim: New York Governor sounds optimistic note as coronavirus numbers improve.
Example Output: New York Governor Andrew Cuomo said on Saturday that a recent drop in hospitalizations and other improving metrics indicated the state may be past the peak of its coronavirus crisis and on a path toward stabilizing its battered healthcare system.

Example Input: Paragraph: Costs of theMRIdian on-table adaptive radiotherapy in comparison to conventional radiotherapy are not discussed. Given that it is new and more personalized than current treatment options it's likely to be correspondingly more expensive. Certainly, more frequent MRIs would be very costly. The release provides exact information about increased survival rates in the cohorts of individuals treated with the adaptive versus the convention radiotherapy techniques. "The cohort receiving a higher dose demonstrated a near doubling of median overall survival (Kaplan-Meier estimated median overall survival of 27.8 months compared to 14.8 months)." The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy. We appreciate that the headline of this release starts with the words "early data" because this report deals with preliminary and retrospective research. It was not a clinical trial. Instead, results are based on retrospectively comparing treatment of two groups of patients at four institutions. Respective comparisons can't account for a host of factors that might influence results. At the end of the news release readers are told that on the basis of these promising results a clinical trial is being planned. With five-year survival rates of 1 to 14%, it would be hard to engage in disease mongering about pancreatic cancer. This research was sponsored by ViewRay, the company that developed the MRIdian system, and the release does a good job calling attention to this. However, according to the published study, at least one of the co-authors received honoraria from ViewRay Medical Systems. Since this was not included in the release we're rating this criteria Not Satisfactory. This study was all about comparing alternatives, so it scores Satisfactory on that criterion. It would have helped readers if alternatives would have been described more in laymen's terms. The news release notes that the next step is a prospective clinical trial and that tells savvy readers that this treatment strategy has a long road of testing ahead. Still, we think the release could have done a better job clarifying that this therapy is not yet ready for patients, outside of the clinical trial. A study that suggests a doubling of median survival is sure to capture the attention of patients newly diagnosed with pancreatic cancer. These patients and their families are closely aware of the glum statistics for the disease. This is a practical concern that the release should have touched on. This technology is indeed novel and unique to ViewRay, though it is becoming available in more and more cancer treatment centers. No unjustifiable language was identified in the news release. Claim: Early data shows nearly 2x prolonged median survival for inoperable pancreatic cancer
Example Output: This news release reports results of a retrospective study comparing conventional radiotherapy for inoperable pancreatic cancer versus an adaptive radiation therapy that allows clinicians to see the tumor in real time and respond to changes on a daily basis. Targeting the tumor more specifically means higher doses of radiation can be used without increasing damage to surrounding tissues. The study, funded by ViewRay, maker of the MRIdian system, is admittedly preliminary. It is to be followed up by a clinical trial. The release would have been more helpful to readers had it mentioned costs and disclosed a conflict of interest between one of the study authors and the device manufacturer. Surgery is an option only for certain less common types of pancreatic cancer. The five-year survival rates for pancreatic cancers that cannot be treated with surgery are 12% to 14% even for those diagnosed in stage I; the five-year survival rate for cancers detected at stage IV is about 1%, according to the American Cancer Society. ACS reminds readers that five-year survival rates are estimates and that "many people live longer often much longer than 5 years." In that context, a treatment that could extend the lives of the 1.5% of Americans who develop pancreatic cancer is big news.

Example Input: Paragraph: The device, known as renal denervation system, is aimed at high blood pressure-patients who are resistant to traditional drug therapies and works by deadening nerves in kidneys. Analysts called the trial results disappointing, even though they did not have very high sales expectations from the device. "The impact of this news on Medtronic should be modest as we only model worldwide revenues (from the device) of ... 1.2 percent of total company sales in 2018," Wells Fargo Securities analyst Larry Biegelsen wrote in a note. However, despite meeting its main safety goal in the trial, Medtronic said it would halt ongoing trials of the device in the United States, Japan and India. The device was launched in Europe in April 2010, but its adoption was slow as austere governments were reluctant to pay for the unconventional technology. Several other medical device makers, including St Jude Medical Inc and Covidien, are also making devices aimed at treating high blood pressure. These devices work by creating tiny scars along nerves in the kidneys - organs that play a pivotal role in regulating blood pressure by sending signals to the brain that can cause blood vessels to constrict. This scarring process is carried out by threading a catheter through the renal arteries from the groin. It deadens the nerves and decreases blood pressure. Medtronic shares were down 2.5 percent at $59.29 in late morning trade on the New York Stock Exchange. They touched a low of $57.92 earlier in the session. Claim: Medtronic's novel hypertension device fails in trials.
Example Output:
Medtronic Inc's experimental device to treat high blood pressure failed to meet its main goal in a clinical trial, sending the company's shares down nearly 5 percent.